The China National Medical Products Administration (NMPA) has approved Akeso, Inc.’s gumokimab (AK111) for the treatment of adult moderate-to-severe plaque psoriasis. According to the company, the monoclonal antibody demonstrated a 94.6% PASI 75 response rate and a 47.7% complete skin clearance rate (PASI 100) at Week 12. The drug is now poised to enter the competitive immunology market with a reduced dosing frequency compared to existing IL-17 inhibitors.
How does gumokimab compare to current psoriasis treatments?
Clinical data indicates that gumokimab offers higher skin clearance rates than other agents in the IL-17 inhibitor class. According to Akeso’s Phase III trial results (AK111-301), the drug achieved a 47.7% PASI 100 response rate at Week 12, compared to 28.6% for other drugs in the same category. By Week 52, the gap widened, with gumokimab reaching a 68.9% PASI 100 rate against the 39.2% reported for competing therapies.
Gumokimab requires only 17 injections annually. This is approximately half the injection burden of other standard IL-17 inhibitors, a shift that researchers suggest could improve patient adherence to long-term treatment plans.
What are the implications for autoimmune disease treatment?
The approval of gumokimab signals a broader strategic push by Akeso to dominate the immunology and inflammation sector. Dr. Xia Yu, CEO of Akeso, stated that the company has developed a portfolio targeting distinct pathogenic pathways. Beyond plaque psoriasis, the company is advancing manfidokimab in late-stage trials and developing the first-in-class IL-4R/ST2 bispecific antibody, AK139. These assets are designed to create a synergistic platform that addresses the 6.7 million psoriasis patients currently in China.
How will this impact patient management?
Standardized, long-term management is necessary for chronic skin conditions, according to Professor Xu Jinhua of Huashan Hospital, Fudan University. Psoriasis often impairs a patient’s work, social functioning, and mental well-being. By providing a treatment that combines rapid onset—with clinical improvement visible by Week 2—with durable long-term clearance, healthcare providers gain a tool to address the “unmet need” for deep, sustained skin relief.
What happens next for the gumokimab pipeline?
Akeso is moving to expand the clinical footprint of its new drug. The Center for Drug Evaluation (CDE) of the NMPA has accepted a supplemental New Drug Application (sNDA) for gumokimab to treat active ankylosing spondylitis. This move suggests that the company is aiming to capture a broader share of the autoimmune market by leveraging the same monoclonal antibody platform across multiple inflammatory indications.
Pro Tip: Evaluating Biologic Therapies
When reviewing new biologic treatments, prioritize metrics like PASI 100 (complete skin clearance) and injection frequency. Lower injection frequency is often a primary factor in maintaining patient compliance over the 52-week maintenance phase of autoimmune therapies.
Frequently Asked Questions
- What is gumokimab? It is an anti-IL-17 monoclonal antibody developed by Akeso to treat moderate-to-severe plaque psoriasis.
- How fast does it work? Clinical studies showed clinically meaningful improvement as early as Week 2.
- Is it approved for other conditions? Currently, it is approved for plaque psoriasis, with an application for active ankylosing spondylitis under review by the NMPA.
- How does the dosing schedule differ from competitors? It requires 17 injections annually, which is roughly half the frequency of other IL-17 inhibitors.
Are you tracking the latest innovations in autoimmune drug development? Subscribe to our newsletter for updates on NMPA approvals and clinical trial breakthroughs.
